Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction-Reference-Cited by-同舟云学术

Indole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection Fraction

Published:2024-02-16 Issue:4 Volume:134 Page:371-389
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circulation Research

Author:

Wang Yu-Chen¹^ORCID,Koay Yen Chin²³^ORCID,Pan Calvin¹,Zhou Zhiqiang¹^ORCID,Tang Wilson^ORCID,Wilcox Jennifer⁴^ORCID,Li Xinmin S.⁴^ORCID,Zagouras Alexia⁵,Marques Francine⁶^ORCID,Allayee Hooman⁷^ORCID,Rey Federico E.⁸^ORCID,Kaye David M.⁹¹⁰^ORCID,O’Sullivan John F.²³¹¹¹²^ORCID,Hazen Stanley L.¹³⁴^ORCID,Cao Yang¹⁴¹⁵,Lusis Aldons J.¹^ORCID

Affiliation:

1. Department of Medicine, Division of Cardiology, Department of Microbiology, Immunology and Molecular Genetics, and Department of Human Genetics, University of California, Los Angeles (Y.-C.W., C.P., Z.Z., A.J.L.).

2. Cardiometabolic Medicine, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, New South Wales, Australia (Y.C.K., J.F.O.).

3. Charles Perkins Centre, Sydney, New South Wales, Australia (Y.C.K., J.F.O.).

4. Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, OH (J.W., X.S.L., S.L.H.).

5. Stanford Department of Medicine, CA (A.Z.).

6. School of Biological Sciences, Faculty of Medicine, Monash University, Clayton, VIC, Australia (F.M.).

7. Departments of Population & Public Health Sciences and Biochemistry & Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles (H.A.).

8. Department of Bacteriology, University of Wisconsin-Madison (F.E.R.).

9. Baker Heart and Diabetes Institute, Melbourne, Australia (D.M.K.).

10. Department of Cardiology, Alfred Hospital, Melbourne, Australia (D.M.K.).

11. Department of Cardiology, Royal Prince Alfred Hospital, New South Wales, Australia (J.F.O.).

12. Faculty of Medicine, TU Dresden, Germany (J.F.O.).

13. Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, OH (W.H.W.T., S.L.H.).

14. Department of Cardiology, the First Affiliated Hospital of USTC (Y.C.), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.

15. School of Basic Medical Sciences (Y.C.), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.

Abstract

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a common but poorly understood form of heart failure, characterized by impaired diastolic function. It is highly heterogeneous with multiple comorbidities, including obesity and diabetes, making human studies difficult. METHODS: Metabolomic analyses in a mouse model of HFpEF showed that levels of indole-3-propionic acid (IPA), a metabolite produced by gut bacteria from tryptophan, were reduced in the plasma and heart tissue of HFpEF mice as compared with controls. We then examined the role of IPA in mouse models of HFpEF as well as 2 human HFpEF cohorts. RESULTS: The protective role and therapeutic effects of IPA were confirmed in mouse models of HFpEF using IPA dietary supplementation. IPA attenuated diastolic dysfunction, metabolic remodeling, oxidative stress, inflammation, gut microbiota dysbiosis, and intestinal epithelial barrier damage. In the heart, IPA suppressed the expression of NNMT (nicotinamide N-methyl transferase), restored nicotinamide, NAD + /NADH, and SIRT3 (sirtuin 3) levels. IPA mediates the protective effects on diastolic dysfunction, at least in part, by promoting the expression of SIRT3. SIRT3 regulation was mediated by IPA binding to the aryl hydrocarbon receptor, as Sirt3 knockdown diminished the effects of IPA on diastolic dysfunction in vivo. The role of the nicotinamide adenine dinucleotide circuit in HFpEF was further confirmed by nicotinamide supplementation, Nnmt knockdown, and Nnmt overexpression in vivo. IPA levels were significantly reduced in patients with HFpEF in 2 independent human cohorts, consistent with a protective function in humans, as well as mice. CONCLUSIONS: Our findings reveal that IPA protects against diastolic dysfunction in HFpEF by enhancing the nicotinamide adenine dinucleotide salvage pathway, suggesting the possibility of therapeutic management by either altering the gut microbiome composition or supplementing the diet with IPA.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference78 articles.

1. Epidemiology of heart failure with preserved ejection fraction

2. Heart failure: What does ejection fraction have to do with it?

3. Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis

4. Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction

5. Epidemiology and clinical course of heart failure with preserved ejection fraction

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic cycles: A unifying concept for energy transfer in the heart;Journal of Molecular and Cellular Cardiology;2024-10

2. NAD metabolism and heart failure: Mechanisms and therapeutic potentials;Journal of Molecular and Cellular Cardiology;2024-10

3. Interactions between Gut Microbiota and Natural Bioactive Polysaccharides in Metabolic Diseases: Review;Nutrients;2024-08-24

4. Gut microbiome shifts in chronic systolic heart failure are associated with disease severity and clinical improvement;2024-08-07

5. Pretreatment with Indole-3-Propionic Acid Attenuates Lipopolysaccharide-Induced Cardiac Dysfunction and Inflammation Through the AhR/NF-κB/NLRP3 Pathway;Journal of Inflammation Research;2024-08